Levothyroxine Sodium Oral Powder
» Levothyroxine Sodium Oral Powder contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of levothyroxine sodium (C15H10I4NNaO4).
Packaging and storage— Preserve in tight, light-resistant containers.
Labeling— Label it to indicate that it is for veterinary use only.
Loss on drying 731 Dry it in vacuum at 60 for 3 hours: it loses not more than 2.0% of its weight.
Assay—
Mobile phase— Prepare a filtered and degassed mixture of water and acetonitrile (65:35) that contains 1 mL of phosphoric acid in each 1000 mL. Make adjustments if necessary (see System Suitability under Chromatography 621).
0.01 M Methanolic sodium hydroxide— Dissolve 400 mg of sodium hydroxide in 500 mL of water. Cool, add 500 mL of methanol, and mix.
Standard preparation— Dissolve an accurately weighed quantity of USP Levothyroxine RS in 0.01 M Methanolic sodium hydroxide, and dilute quantitatively and stepwise with 0.01 M Methanolic sodium hydroxide to obtain a solution having a known concentration of about 4 µg per mL.
Assay preparation— Transfer an accurately weighed portion of Oral Powder, equivalent to about 5 mg of levothyroxine sodium, to a 250-mL volumetric flask. Dilute with 0.01 M Methanolic sodium hydroxide to volume, mix, and allow to stand for 4 hours, with occasional mixing. Pass a portion of this mixture through a filter that does not absorb levothyroxine. Transfer 10.0 mL of the filtrate to a 50-mL volumetric flask, dilute with 0.01 M Methanolic sodium hydroxide to volume, and mix.
Chromatographic system (see Chromatography 621) The liquid chromatograph is equipped with a 225-nm detector and a 4.6-mm × 25-cm column that contains packing L10. The flow rate is about 1 mL per minute. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the tailing factor is not more than 1.8; and the relative standard deviation for replicate injections is not more than 2.0%.
Procedure— Separately inject equal volumes (about 50 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the responses for the major peaks. Calculate the quantity, in mg, of levothyroxine sodium (C15H10I4NNaO4) in the portion of Oral Powder taken by the formula:
(798.85 / 776.87)(1.25C)(rU / rS)
in which 798.85 and 776.87 are the molecular weights of levothyroxine sodium and levothyroxine, respectively; C is the concentration, in µg per mL, of USP Levothyroxine RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Ian DeVeau, Ph.D.
Director, Veterinary Drugs and Radiopharmaceuticals
1-301-816-8178
(VET05) Veterinary Drugs 05
Reference Standards Lili Wang, Technical Services Scientist
1-301-816-8129
RSTech@usp.org
USP32–NF27 Page 2778
Pharmacopeial Forum: Volume No. 34(4) Page 954
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.